Methotrexate (MTX) plasma concentration is routinely monitored to guide the dosage regimen of rescue drugs. This study aims to develop and validate an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/ MS) method for plasma MTX analysis, and to establish its agreement with the fluorescence polarization immunoassay (FPIA) in patients with high-dose MTX therapy. Separation was achieved by gradient elution with methanol and water (0.05% formic acid) at 40 C with a run time of 3 min. The intra-and inter-day inaccuracy and imprecision of the UPLC-MS/MS method were -4.25 to 3.1 and less than 7.63%, respectively. The IS-normalized recovery and matrix effect were 87.05 to 92.81 and 124.43 to 134.57%. The correlation coefficients between UPLC-MS/MS and FPIA were greater than 0.98. The UPLC-MS/MS method was in agreement with the FPIA at high levels of MTX (1.0 -100 μmol/L), but not at low levels (0.01 -1.0 μmol/L). Further studies are warranted to confirm these results.
Introduction
Methotrexate (MTX), a dihydrofolate reductase inhibitor, has been clinically used for over 5 decades. High-dose MTX has improved the survival rates in treating patients with primary central nervous system lymphoma and other malignant tumors. 1 With intravenous infusion, about 80 to 90% of the administered dose is excreted to be unchanged in the urine within 24 h. 1 Delayed drug excretion has been identified as the major factor responsible for MTX toxicity, which is more dependent on the duration of exposure to the drug rather than the peak level achieved. 1 To avoid fatal toxicity of MTX, calcium folinate rescue is conventionally used, and its dosage regimen is subjected to the plasma concentration of MTX. 1 Therefore, plasma MTX is routinely monitored in high-dose MTX therapy to guide the dosage regimen of rescue drugs.
Various kinds of methods have been used for plasma MTX determination, including fluorescence polarization immunoassay (FPIA), 2 high-performance liquid chromatography (HPLC), 3 liquid chromatography tandem mass spectrometry (LC-MS/ MS), [4] [5] [6] [7] [8] [9] [10] [11] [12] capilary electrophoresis with laser-induced fluorescence detection, 13 and chemiluminescent microparticle immunoassay. 14 In clinical practice, FPIA is the most commonly used method in plasma MTX monitoring owing to its simplicity in sample preparation and a relatively short run time. 2 However, it has many limitations: (1) The mouse monoclonal antibodies may interfere with the immunoassays. 15 (2) Patients with a high MTX level who have received carboxypeptidase G2 may have an increased serum level of 2,4-diamino-N 10 -methylpteroic acid, which could cross-react with the MTX antibody. 16 (3) Folates and MTX metabolites, such as 7-hydroxy-MTX, could bind to the MTX antibody and influence the result.
17 (4) The range of the plasma MTX level is wide in high-dose MTX therapy, and thus serial dilution is needed prior to a test. 18 On the other hand, the poor selectivity and sensitivity of the ultraviolet and fluorescence detectors used in HPLC methods, the relatively small molar absorption coefficient of MTX, and the low plasma concentration of MTX in patients restrict the widespread application of the HPLC method in plasma MTX analysis. 4, 8, 9, 19 With powerful selectivity and sensitivity, many LC-MS/MS methods were developed to determine plasma MTX. [4] [5] [6] [7] [8] [9] [10] [11] [12] 19 However, there were many limitations in previous methods, such as the relatively large sample volume requirements, 6, 9, 12 the time-consuming process in sample preparation, 6, 12 and a long turnaround time in analysis. [4] [5] [6] [7] [8] [10] [11] [12] 19 In the present study, an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the analysis of MTX in human plasma was developed, validated and applied in 172 samples, which were also tested by FPIA. The agreement between UPLC-MS/MS and FPIA was evaluated by Bland-Altman plot.
Experimental

Materials
Methotrexate (100138-201104, 99.4% purity) and ticlopidine (internal standard, IS, 100542-201002, 99.7% purity) were purchased from the National Institutes for Food and Drug Control (Beijing, China). HPLC grade methanol and formic acid were purchased from Fisher Scientific (USA). Ultrapure water was generated from a water-purification device (Millipore, Bedford, MA). Drug-free plasma was obtained from eight healthy volunteers.
Equipment
Chromatographic analysis was performed on an Acquity UPLC H-Class (Waters, MA) tandem QTRAP 5500 mass system (AB SCIEX, CA). Data were acquired and processed by using the AB SCIEX Analyst software (Ver. 1.6). The FPIA was carried out on a TDx analyzer with the methotrexate II assay (Abbott Diagnostics, Chicago, IL).
Measurement conditions
Chromatographic separation was achieved on a Waters Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm particles). The gradient elution was performed with mobile phases A (methanol) and B (0.05% formic acid in water) as follows: initial, 10% A; 0 -0.7 min, 10% A -90% A; 0.7 -1.5 min, 90% A; 1.5 -1.6 min, 90% A -10% A; 1.6 -3.0 min, 10% A. The flow rate was 0.4 mL/min with an injection volume of 2 μL. The temperature of the autosampler and the column oven was set at 10 and 37 C.
Positive electrospray ionization was performed at 550 C, and the ion spray voltage was 5500 V; the pressures of ion source gas 1, ion source gas 2, and curtain gas were 50, 50, and 30 psi, respectively. Medium collision gas was used. The declustering potential, collision energy, entrance potential, and collision cell exit potential were 100, 26, 10, and 10 V for MTX, and 100, 38, 10, and 10 V for IS, respectively. Multiple reaction monitoring transitions were performed for quantitation at m/z 455.2 > 308.2 for MTX and m/z 264.1 > 125.0 for IS (Fig. 1) .
Preparation of stock solutions, calibration and quality control (QC) standards
Stock solutions of MTX and IS were prepared by dissolving accurately weighed standard compounds in ultrapure water or methanol to obtain a concentration of 1000 μmol/L for MTX (10 μL of 1 mol/L NaOH was added to dissolve MTX) and IS. By spiking drug-free plasma with the appropriate working solutions and IS, a series of calibration samples were prepared at concentrations of 0.01, 0.05, 0.1, 0.5, 1, and 5 μmol/L. The concentration of IS was 0.1 μmol/L. Separately weighed stocks of standards were used to prepare five QC samples: lowest limit of quantitation (LLOQ), low, low-medium, high-medium, and high levels with the concentration of 0.01, 0.02, 0.2, 2, and 4 μmol/L. All solutions were stored at -80 C before use.
Patient enrollment, sample collection and preparation
This study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. After informed consents were obtained from patients or their direct relatives, ethylene diamine tetraacetic acid anticoagulated blood samples were collected. Samples were centrifuged immediately at 3630 × g for 10 min, then 100 μL of the supernatant and 10 μL of IS (1 μmol/L) were added into a 500-μL Eppendorf tube. Then, 300 μL of methanol was added into the 500-μL tube, after being vortex mixed for 1 min, the mixture was centrifuged at 10000 × g for 2 min to precipitate the proteins. Subsequently, 20 μL of the supernatant was mixed with a 180-μL mixture of methanol and water (50:50, v/v). After being vortex mixed for 1 min and centrifuged at 10000 × g for 2 min, 2 μL of the supernatant was injected into the UPLC-MS/MS system for analysis.
Method validation-lowest limit of quantitation and selectivity
A method validation was performed according to the guidelines. 22, 23 Drug-free plasma from eight individuals was used to evaluate the selectivity. The lowest concentration of the calibration curves was regarded as the LLOQ (0.01 μmol/L). The inter-day and intra-day accuracy and precision of LLOQ samples were evaluated by analyzing 5 replicates of the LLOQ samples on 5 consecutive days.
Method validation-carry-over effect and linearity
Immediately following the highest concentration of the calibration sample, a blank sample was injected to test the carryover effect of MTX and IS. A weighted least-squares method (weighting factor = 1/x 2 ) was used to fit the peak area ratio vs. analyte concentrations for linearity over the range of 0.01 to 5 μmol/L.
Method validation-accuracy and precision
To evaluate the intra-day and inter-day accuracy and precision, five replicates of QC samples at LLOQ, low, low-medium, highmedium, and high levels (0.01, 0.02, 0.2, 2, 4 μmol/L) were analyzed on the same day and on five consecutive days. 
Method validation-recovery and matrix effect
To evaluate the recovery and the matrix effect, drug-free plasma from eight individuals was used, and three batches (each contain four QC levels, 0.02, 0.2, 2, and 4 μmol/L) were prepared as follows: (A) MTX and IS spiked in blank plasma and treated by protein precipitation; (B) pure solvent containing an equivalent amount of MTX and IS; (C) MTX and IS spiked in post-protein precipitated blank plasma from eight different individuals. For the three batches, eight replicates of QC samples at four levels were analyzed. The recovery and matrix factor were represented as (A/C × 100)% and (C/B × 100)%. The IS-normalized recovery and the matrix effect were represented as (AMTX/CMTX)/(AIS/CIS) × 100% and (CMTX/BMTX)/ (CIS/BIS) × 100%.
Method validation-dilution integrity
Because of the wide range of the plasma MTX levels in patients with high-dose MTX therapy, and the limited linear range of mass spectrometry, sample dilution was required. Therefore, ten-fold, fifty-fold, and two hundred and fifty-fold dilutions of QC samples at eight times, forty times, and two hundred times of the highest calibration curve were used to evaluate the dilution integrity by analyzing 5 replicates of the diluted samples.
Method validation-stability
The stability of MTX in human plasma should be evaluated to guide the measurement. In routine drug monitoring, the preparation of calibration and QC samples is a hard work for analysts. By establishing the stability of analytes in processed plasma matrix, analysts could store the processed calibration and QC samples under stable conditions to save their time for preparing calibration and QC samples. The stability of MTX in plasma or the processed plasma matrix (20 μL of the supernatant mixed with 180 μL mixture of methanol and water (50:50, v/v)) was evaluated by using five replicates of QC samples at four QC levels. The observed concentrations were compared to the nominal concentrations; the deviation within ± 15% was regarded as stable. 23 The storage conditions for MTX in plasma are listed below: 22 C for 24 h, -80 C for 24 h, three freezethaw cycles from -80 to 22 C, and -80 C for 62 days. The stability of MTX in processed plasma matrix was evaluated under the following conditions: 22 C for 24 h, 10 C for 24 h, two freeze-thaw cycles from -80 to 22 C, and -80 C for 62 days.
Method application and comparison
A total of 172 samples were analyzed by the two methods. The agreement of the two methods was evaluated by a BlandAltman plot. 20, 21 The Passing-Bablok regression and Pearson test were used to obtain the equation and the correlation coefficient of the two methods. 24 The mean values of the two methods were evaluated by a paired samples t-test or Wilcoxon test.
Statistical analysis
SPSS (Ver. 17, SPSS Inc., Chicago, IL) and MedCalc (Ver. 15.8, MedCalc Software bvba, Ostend, Belgium) software were used for statistical analysis. The statistical significance was defined as P < 0.05.
Results and Discussion
Method development
The maximum pressure of the UPLC system used in the present study is 15000 psi. The triple quadrupole mass system (5500, AB SCIEX) is sensitive and the most sensitive ion pair of MTX (m/z 455.2 > 308.2) was chosen for quantitation. The combination of the two powerful systems allows the use of columns with small particle size under a high flow rate to obtain a high column efficiency, a narrow peak shape and a relative short run time. The particle size of the column used in the present study was 1.7 μm with a flow rate of 0.4 mL/min; therefore, a high signal-to-noise ratio of LLOQ samples (177.8) and a short run time (3 min) were achieved. Moreover, the signal-to-noise ratio of LLOQ samples was high despite dilution during sample processing; therefore, an one-step protein precipitation by methanol could be used, which was more convenient and economical than previous methods. 6, 12 Acetonitrile was used for separation in most of the published studies, 4-6,8-11 whereas a more economical solvent methanol was used in the present study. 12 The whole run time of a sample was 3.0 min, which was faster than most of the previous methods.
4-8,10-12 The 2 μL injection volume was smaller than most of the reported methods with acceptable sensitivity.
5-11
The linearity range was 0.01 to 5 μmol/L, extended by the dilution factor (10, 50 and 250), the method could meet the clinical requirements. 1 
Lowest limit of quantitation and selectivity
The signal-to-noise ratio of the LLOQ samples was 177.8. Figure 2 illustrates typical multiple reaction monitoring chromatograms of the method. No endogenous peaks were observed and IS did not interfere with the analysis of MTX. For LLOQ samples, the inaccuracy was -8.77 to 4.34% and the imprecision was less than 12.42% (data not shown). The concentration of the LLOQ (0.01 μmol/L) was low enough for clinical use, and was lower than the values in many studies.
4,5
Carry-over effect and linearity
No carry-over effect was observed. The typical linearregression equation was y = 4.21x + 0.0129 (x, MTX concentrations; y, peak area ratios of MTX/IS, r = 0.999).
Accuracy and precision
The intra-day and inter-day inaccuracy at five QC levels were -3.05 to 3.00 and -4.25 to 3.10%, respectively ( Table 1) . The intra-day and inter-day imprecision for MTX at five QC levels were less than 7.63 and 5.52%, respectively. The results indicated that the method is both accurate and precise.
Recovery and matrix effect
The IS-normalized recovery and matrix effect are listed in Table 2 . The absolute recovery and matrix effect of MTX were 90.12 to 101.05 and 110.47 to 123.33%, respectively. The ISnormalized recovery and matrix effect of MTX were 87.05 to 92.81 and 124.43 to 134.57%, respectively. The coefficient variation of the recovery and matrix effect were 0.47 to 6.99% and 0.81 to 3.32%, respectively, which were in accordance with the guidelines. 22, 23 The recovery and matrix effect values in the present study were similar to the those in a previous study (human plasma). 4 
Dilution integrity
The acceptable inaccuracy and imprecision of the diluted samples were 2.87 to 4.48 and less than 5.71%, respectively.
22,23
Stability
The stability results are given in Table 3 (MTX in plasma) and Table 4 (MTX in processed plasma matrix). MTX was stable in plasma or processed plasma matrix at room temperature (about 22 C) for at least 8 and 24 h (the inaccuracy was -2.95 to 8.50 and 2.90 to 6.17%, respectively). MTX did not change during a freeze-thaw treatment (the inaccuracy was 3.88 to 12.75% in plasma and -1.50 to 7.00% in processed plasma matrix). In a long-term stability test at -80 C for 62 days, the inaccuracy of MTX in the plasma and processed plasma matrix was -5.38 to 2.67 and -4.56 to 1.63%. MTX was stable in the processed plasma matrix in an autosampler (10 C) for at least 24 h. The stability of MTX in human plasma was in accordance with previous results (human plasma or rat plasma matrix). 4, 7 MTX was stable in the processed plasma matrix under the tested conditions, which may greatly save time in the preparation of calibration and QC samples.
Method application and comparison
The MTX measurements detected by FPIA and LC-MS/MS were abnormally distributed at low levels (0.01 -1.0 μmol/L) and high levels (1.0 -100 μmol/L). line of equality (y = x). Besides, the range of the true value of the samples could affect the correlation. Moreover, the same mean value did not mean that the two methods were in agreement with each other, and a Bland-Altman plot was appropriate to evaluate the agreement of the two methods. 20, 21 The difference of the two methods had an abnormal distribution at both low and high concentrations of MTX (P <0.034, Kolmogorov-Smirnov test).
The correlation between the difference and magnitude were not observed at both levels; thus, a direct comparison could be performed. 20, 21 Without any extreme discrepancies between the two methods, the abnormal distribution of the differences will not greatly affect the 95% LOA. 20 At low levels of MTX, a bias of 0.019 μmol/L was observed between the two methods; the mean of the difference of the two methods was statistically not the same as zero (P <0.0001); the 95% limits of agreement (95% LOA) was -0.077 to 0.11 μmol/L; ten samples (10/154, 6.67%) fell outside the range of the 95% LOA (Fig. 3C) . However, some of the MTX values were lower in the FPIA group than that in the UPLC-MS/ MS group at low levels. This might be due to the deviation of both methods. At high levels of MTX, a bias of -0.42 μmol/L was observed between the two methods; the mean of the difference of the two methods was statistically the same as zero (P = 0.30); the 95% LOA was -4.87 to 4.03 μmol/L; two samples (2/32, 6.25%) fallen outside the range of the 95% LOA (Fig. 3D) . At high levels of MTX, the two methods were in agreement with each other, 14, 17, 19 while an opposite result was obtained at low levels of MTX. The mean values of MTX was higher in the FPIA group compared to the UPLC-MS/MS group at low levels; this overestimation may be caused by the folates or the MTX metabolites 7-hydroxy-MTX 19 and 2,4-diamino-N 10 -methylpteroic acid. 2, 18 Strong correlations were observed between the two methods (>0.98) and conversion of the values by the equations may be useful in clinical practice.
Deficiencies of the study
(1) At high levels of MTX (>5 μmol/L), a manual dilution was required for the UPLC-MS/MS method. To avoid manual dilution of the sample, the linearity range should be expanded by using the following strategies: (a) reduce the plasma volume; (b) increase the dilution ratio during sample preparation; (c) adjust the injection volume. (2) The concentration of MTX metabolites may increase by time after infusion, however we did not group samples by sampling time because sampling time varied greatly among patients. (3) All samples were tested once by each method; therefore, the repeatability of both methods could not be evaluated. 20 ,21 (4) The MTX concentration could not be tested by our method in patients taking ticlopidine (internal standard). In this case, FPIA is an alternative method for the MTX measurement. In our further study, the use of an isotopic internal standard (MTX-d3, CAS number: 432545-63-6) could solve this problem. (5) At high concentrations, only 32 samples were used for method comparison, which was much smaller than recommended (100) to obtain a stable result. 25 (6) The agreement of the two methods was a clinical judgment, and hence more clinical information is needed. 20, 21 An UPLC-MS/MS method for MTX analysis in human plasma was developed, validated and applied in 172 samples. The UPLC-MS/MS method was in agreement with FPIA at high levels but not at low levels. Further studies are warranted to confirm these results.
